# Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity		
OBJ LIMITED		
ABN		
72 056 482 636		

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 +Class of +securities issued or to be issued
- 1) Ordinary fully paid shares (**Shares**).
- 2) Listed options to acquire Shares (**Options**).
- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- 1) 235,099,450 Shares.
- 2) Up to 180,495,707 Options.

+ See chapter 19 for defined terms.

- Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)
- Shares and Options will be issued on the terms set out in the prospectus dated 15 March 2013 and lodged with ASX and ASIC on the same date (**Prospectus**).
  - Shares are issued pursuant to the "Rights Issue Offer" set out in section 1 of the Prospectus – terms of the Shares are summarised in section 6.1 of the Prospectus
  - 2) Options are issued pursuant to the "Rights Issue Offer" and the "Option Offer" set out in sections 1 and 2 of the Prospectus Options are exercisable at \$0.01 each on or before 31 December 2014, on the terms summarised in section 6.2 of the Prospectus

4 Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

- 1) Yes.
- 2) No. Options are exercisable in accordance with the terms summarised in section 6.2 of the Prospectus and upon conversion of the Options, the Shares allotted will rank equally in all respects with the existing ordinary fully paid shares of the Company. The Options do not carry entitlements to dividends.

- 5 Issue price or consideration
- 1) \$0.015 per Share.
- 2)
- a. 94,039,780 Options issued for nil consideration pursuant to the Rights Issue Offer.
- b. up to 86,455,927 Options issued for \$0.001 per option pursuant to the Option Offer.

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

The funds raised by the Company via the Rights Issue Offer and Option Offer will be applied by the Company to advance its own program including products Musculoskeletal and Pain Management development, Clinical Development Programs, **Property** and Technology Intellectual Expansion Programs, with the balance of the funds (after expenses of the offer) being applied to general working capital purposes, as detailed in section 3.1 of the Prospectus.

6a Is the entity an <sup>+</sup>eligible entity that has obtained security holder approval under rule 7.1A?

Yes

If Yes, complete sections 6b – 6h in relation to the \*securities the subject of this Appendix 3B, and comply with section 6i

6b The date the security holder resolution under rule 7.1A was passed

26 November 2012

6c Number of \*securities issued without security holder approval under rule 7.1

Up to 86,455,927 Options pursuant to the Option Offer.

6d Number of \*securities issued with security holder approval under rule 7.1A

Nil.

6e Number of \*securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

Nil.

6f Number of \*securities issued under an exception in rule 7.2

1) 235,099,450 Shares; and

2) 94,039,780 Options, pursuant to the Rights Issue Offer.

6g If \*securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the \*issue date and both values. Include the source of the VWAP calculation.

N/A.

<sup>+</sup> See chapter 19 for defined terms.

6h	If +securities were issued under	]
	rule 7.1A for non-cash	
	consideration, state date on which	
	valuation of consideration was	
	released to ASX Market	
	Announcements	

N/A.

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

7.1-139,239,545 (or such greater number if the Option Offer is not fully subscribed) 7.1A-150,463,648

#### 7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

26 April 2013.

8 Number and \*class of all \*securities quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class
1,410,596,700	Ordinary fully paid shares.
86,455,927	Options exercisable at \$0.01 on or before 30/6/13.
180,495,707	Options exercisable at \$0.01 on or before 31/12/14.

9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
33,000,000	Performance Rights

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

No policy exists

## Part 2 - Pro rata issue – Rights Issue Offer only

11	Is security holder approval required?	No
12	Is the issue renounceable or non-renounceable?	Non-renounceable
13	Ratio in which the *securities will be offered	1 new ordinary fully paid share for every five existing ordinary fully paid shares as at the record date (see # 15 below) plus two free attaching new options for every five new shares subscribed for and allotted under the Rights Issue Offer.
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	<ol> <li>Ordinary fully paid shares.</li> <li>Listed options exercisable at \$0.01 on or before 31/12/14. Shares issued upon exercise of Options will rank equally in all respects with the Company's existing fully paid ordinary shares.</li> </ol>
15	<sup>+</sup> Record date to determine entitlements	26 March 2013
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	No
17	Policy for deciding entitlements in relation to fractions	Fractional entitlements will be rounded up to the nearest whole number. See section 1.4 of the Prospectus.
18	Names of countries in which the entity has security holders who will not be sent new offer documents	All countries other than Australia and New Zealand.
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	17 April 2013

<sup>+</sup> See chapter 19 for defined terms.

20	Names of any underwriters	Novus Capital Limited
21	Amount of any underwriting fee or commission	<ul> <li>(a) 5% of amount underwritten as an underwriting fee.</li> <li>(b) 1% of amount underwritten as a management fee.</li> <li>(c) \$35,000 advisory Fee.</li> <li>(d) 5,000,000 new options exercisable at \$0.01 on or before 31/12/14.</li> <li>Refer to section 8.2 of the Prospectus.</li> </ul>
22	Names of any brokers to the issue	Novus Capital Limited
23	Fee or commission payable to the broker to the issue	As stated in #21 above.
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	3 April 2013
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	15 March 2013
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

32	their e	o security holders dispose of ntitlements (except by sale a a broker)?	N/A
33	<sup>+</sup> Issue o	late	26 April 2013
		notation of securitie	
34	Type of	f +securities e)	
(a)		*Securities described in Part 1	
(b)			of the escrowed period, partly paid securities that become fully paid, employee ends, securities issued on expiry or conversion of convertible securities
Entitie	es that	have ticked box 34(a)	
Additi	ional se	curities forming a new cla	ss of securities
Tick to docume		you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the number and percentage of additional *securities held by
36			y securities, a distribution schedule of the additional ber of holders in the categories – <i>to be provided</i>
37		A copy of any trust deed for the	ne additional *securities – <i>not applicable</i>

<sup>+</sup> See chapter 19 for defined terms.

### Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought	N/A	
39	*Class of *securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state: • the date from which they do		
	<ul> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>		
41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and +class of all +securities	N/A	N/A
42	quoted on ASX (including the +securities in clause 38)	IV/A	IV/A

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Date: 15 March 2013

Sign here:

(Director/Company secretary)

JEFFREY EDWARDS

Print name:

04/03/2013 Appendix 3B Page 9

\_ \_\_ \_\_ \_\_ \_\_

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	1,155,956,528	
<ul> <li>Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> <li>Subtract the number of fully paid +ordinary securities cancelled during that 12 month period</li> </ul>	Fully paid ordinary securities issued in the 12 month period under an exception in rule 7.2:  (a) 320,000 (31 July 2012)  (b) 11,220,722 (18 January 2013)  (c) 4,000,000 (22 January 2013)  (d) 4,000,000 (31 January 2013)  (a) 235,099,450 (26 April 2013)  (b) 94,039,780 (26 April 2013)	
"A"	1,504,636,480	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	225,695,472	
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule	
<b>Insert</b> number of +equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	86,455,927	
• Under an exception in rule 7.2		
Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	86,455,927	
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15	225,695,472	
Note: number must be same as shown in Step 2		
Subtract "C"	86,455,927	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	139,239,545	
	[Note: this is the remaining placement capacity under rule 7.1]	

<sup>+</sup> See chapter 19 for defined terms.

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	1,504,636,480	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10	150,463,648	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	Nil	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	150,463,648	
Note: number must be same as shown in Step 2		
Subtract "E"	Nil	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	150,463,648	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.